Hyperkalemia | Current Treatment | EU5 | 2016
Hyperkalemia is an important complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD) with significant impacts on morbidity and mortality. Management of hyperkalemia is dependent on both patient symptoms and the elevation of serum potassium levels, and it typically involve potassium binders to control potassium levels in the body. These potassium binders have a significant side-effect profile; therefore, tolerable and effective treatments are needed. This content provides an in-depth examination of the different treatment and prescribing practices for hyperkalemia within Europe and offers insights for companies seeking to enter this market.
Related Market Assessment Reports
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…
